AU2012325819B2 - Therapeutic combination for the treatment of cancer - Google Patents

Therapeutic combination for the treatment of cancer Download PDF

Info

Publication number
AU2012325819B2
AU2012325819B2 AU2012325819A AU2012325819A AU2012325819B2 AU 2012325819 B2 AU2012325819 B2 AU 2012325819B2 AU 2012325819 A AU2012325819 A AU 2012325819A AU 2012325819 A AU2012325819 A AU 2012325819A AU 2012325819 B2 AU2012325819 B2 AU 2012325819B2
Authority
AU
Australia
Prior art keywords
cisplatin
therapeutic combination
cancer
nerium
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012325819A
Other languages
English (en)
Other versions
AU2012325819A1 (en
Inventor
Dennis R. Knocke
Joseph B. Nester
Ioannis PAPASOTIRIOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerium Biotechnology Inc
Original Assignee
Nerium Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerium Biotechnology Inc filed Critical Nerium Biotechnology Inc
Publication of AU2012325819A1 publication Critical patent/AU2012325819A1/en
Application granted granted Critical
Publication of AU2012325819B2 publication Critical patent/AU2012325819B2/en
Priority to AU2017254875A priority Critical patent/AU2017254875A1/en
Priority to AU2019203577A priority patent/AU2019203577A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2012325819A 2011-10-20 2012-10-20 Therapeutic combination for the treatment of cancer Ceased AU2012325819B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017254875A AU2017254875A1 (en) 2011-10-20 2017-10-31 Therapeutic combination for the treatment of cancer
AU2019203577A AU2019203577A1 (en) 2011-10-20 2019-05-21 Therapeutic combination for the treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549386P 2011-10-20 2011-10-20
US61/549,386 2011-10-20
PCT/US2012/061226 WO2013059753A1 (en) 2011-10-20 2012-10-20 Therapeutic combination for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017254875A Division AU2017254875A1 (en) 2011-10-20 2017-10-31 Therapeutic combination for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2012325819A1 AU2012325819A1 (en) 2014-04-24
AU2012325819B2 true AU2012325819B2 (en) 2017-08-03

Family

ID=48141445

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2012325819A Ceased AU2012325819B2 (en) 2011-10-20 2012-10-20 Therapeutic combination for the treatment of cancer
AU2017254875A Abandoned AU2017254875A1 (en) 2011-10-20 2017-10-31 Therapeutic combination for the treatment of cancer
AU2019203577A Abandoned AU2019203577A1 (en) 2011-10-20 2019-05-21 Therapeutic combination for the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017254875A Abandoned AU2017254875A1 (en) 2011-10-20 2017-10-31 Therapeutic combination for the treatment of cancer
AU2019203577A Abandoned AU2019203577A1 (en) 2011-10-20 2019-05-21 Therapeutic combination for the treatment of cancer

Country Status (13)

Country Link
US (2) US20130209579A1 (enExample)
EP (2) EP2768498B1 (enExample)
JP (1) JP6255346B2 (enExample)
CN (2) CN104093405A (enExample)
AU (3) AU2012325819B2 (enExample)
BR (1) BR112014009421A2 (enExample)
CA (1) CA2852274C (enExample)
GT (1) GT201400071A (enExample)
IL (2) IL231987B (enExample)
IN (1) IN2014KN00796A (enExample)
MX (2) MX365635B (enExample)
RU (2) RU2017136415A (enExample)
WO (1) WO2013059753A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186487B (zh) * 2008-10-14 2013-05-15 奈瑞姆生物技术公司 提取强心苷的方法和组合物
CN107530309A (zh) * 2015-04-22 2018-01-02 新纳特产品公司 共晶组合物及其药物用途
PH12018500691B1 (en) * 2015-10-05 2022-08-10 NuCana plc Combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154573A1 (en) * 2005-12-27 2007-07-05 Juay Jamil Rashan Method of preparing and using a cold extract from the leaves of nerium oleander

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1299100C (en) 1986-05-13 1992-04-21 Huseyin Ziya Ozel Extracts of nerium species, methods of preparation and use therefor
WO2000016793A1 (en) 1998-09-24 2000-03-30 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US7407675B2 (en) * 2002-12-27 2008-08-05 The Trustees Of Columbia University In The City Of New York Anti-neoplastic compositions comprising extracts of black cohosh
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
PL2173337T3 (pl) 2007-08-06 2014-11-28 Univ Ohio Fosfaplatyny i ich zastosowanie w leczeniu raków opornych na cisplatynę i karboplatynę
CN102186487B (zh) * 2008-10-14 2013-05-15 奈瑞姆生物技术公司 提取强心苷的方法和组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154573A1 (en) * 2005-12-27 2007-07-05 Juay Jamil Rashan Method of preparing and using a cold extract from the leaves of nerium oleander

Also Published As

Publication number Publication date
GT201400071A (es) 2015-09-17
RU2014120179A (ru) 2015-11-27
AU2019203577A1 (en) 2019-06-13
CN110269940A (zh) 2019-09-24
EP2768498A1 (en) 2014-08-27
CN104093405A (zh) 2014-10-08
IL275636A (en) 2020-08-31
IN2014KN00796A (enExample) 2015-10-02
NZ623550A (en) 2016-06-24
EP3711754A1 (en) 2020-09-23
WO2013059753A1 (en) 2013-04-25
IL231987A0 (en) 2014-05-28
MX365635B (es) 2019-06-10
JP2014530878A (ja) 2014-11-20
IL231987B (en) 2020-07-30
RU2017136415A3 (enExample) 2021-02-08
US20190343908A1 (en) 2019-11-14
EP2768498A4 (en) 2015-06-17
AU2012325819A1 (en) 2014-04-24
MX2014004527A (es) 2014-09-15
RU2017136415A (ru) 2019-02-08
US20130209579A1 (en) 2013-08-15
CA2852274A1 (en) 2013-04-25
BR112014009421A2 (pt) 2017-04-18
AU2017254875A1 (en) 2017-11-23
MX2019006685A (es) 2019-08-21
EP2768498B1 (en) 2020-03-04
CA2852274C (en) 2019-08-06
JP6255346B2 (ja) 2017-12-27

Similar Documents

Publication Publication Date Title
Banerjee et al. Oxidative stress triggered by naturally occurring flavone apigenin results in senescence and chemotherapeutic effect in human colorectal cancer cells
Roh et al. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis
Farrand et al. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission
Cohen et al. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers
Tripathi et al. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors
Zhang et al. Polyphenol-rich extract of Pimenta dioica berries (Allspice) kills breast cancer cells by autophagy and delays growth of triple negative breast cancer in athymic mice
Yan et al. ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway
Zhao et al. Total ginsenosides extract induce autophagic cell death in NSCLC cells through activation of endoplasmic reticulum stress
Zhang et al. Artematrolide A inhibited cervical cancer cell proliferation via ROS/ERK/mTOR pathway and metabolic shift
Gao et al. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma
Kim et al. A novel herbal medicine, KIOM-C, induces autophagic and apoptotic cell death mediated by activation of JNK and reactive oxygen species in HT1080 human fibrosarcoma cells
US20190343908A1 (en) Therapeutic Combination for the Treatment of Cancer
Li et al. Matrine induces autophagic cell death by triggering ROS/AMPK/mTOR axis and apoptosis in multiple myeloma
Jang et al. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway
Yin et al. Combined Levo-tetrahydropalmatine and diphenyleneiodonium chloride enhances antitumor activity in hepatocellular carcinoma
Hu et al. A novel strategy to enhance inhibition of Hela cervical cancer by combining Lentinus β-glucan and autophagic flux blockage
CN109864991A (zh) 隐丹参酮在制备Ph+急性淋巴细胞白血病化疗增敏药物中的应用
Kim et al. Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E
Wu et al. Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer
Putri et al. Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells
Kuduvalli et al. A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo
Yue et al. UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells
Liu et al. HTBPI, an active phenanthroindolizidine alkaloid, inhibits liver tumorigenesis by targeting Akt
Liu et al. 3-Epi-betulinic acid 3-O-β-D-glucopyranoside (eBAG) induces autophagy by activation of AMP-activated protein kinase in hepatocellular carcinoma
De et al. Polyphenol-rich fraction of Bergenia ligulata regresses colon and breast cancer metastasis by cell-type specific mechanism

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired